Navigation Links
VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
Date:6/7/2011

TARRYTOWN, N.Y. and BERLIN, June 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion (CRVO), diabetic macular edema (DME), and myopic choroidal neovascularization (mCNV).

"The submission of VEGF Trap-Eye for EU marketing authorization represents a significant milestone in our goal to bring this potentially important new therapy to patients with wet AMD across the globe," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.

The VEGF Trap-Eye submission is based on the positive results from two Phase 3 trials, the VIEW 1 study and the VIEW 2 study.  In these trials, all regimens of VEGF Trap-Eye, including 2 mg VEGF Trap-Eye dosed every two months (following three loading doses), successfully met the primary endpoint of non-inferiority, compared to the current standard of care, ranibizumab 0.5 mg dosed every month.  The primary endpoint analysis was statistical non-inferiority in the proportion of patients who maintained (or improved) vision over 52 weeks compared to ranibizumab at the dose that is currently known to provide the best possible efficacy.  A generally favorable safety profile was observed for both VEGF Trap-Eye and ranibizumab.  The ocular adverse events were balanced across all treatment groups in both studies.  There were no notable differences in non-ocular adverse events among the study arms.

Regeneron submitted a Biologics License Application (BLA) for marketing approval in wet
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
4. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
5. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
6. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
7. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Vemurafenib New Drug Application Submitted to FDA for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ... drug delivery systems, today announced that its Chairman and ... at the Piper Jaffray 26th Annual Healthcare Conference at ... on Tuesday, December 2, 2014. The ... a "live" listen only Webcast. To listen, please go ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 ... (NYSE: AZN ) today announced that AMAGINE-2 TM ... of brodalumab in more than 1,800 patients with moderate-to-severe plaque ... ® (ustekinumab) and placebo at week 12. Brodalumab 210 ... group were each shown to be superior to Stelara on ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... 10, 2011 Nephros, Inc. (OTC Bulletin Board: ... by the Food and Drug Administration ("FDA") of the 510(k) ... On August 11, 2011 Nephros submitted a new 510(k) ... disease.  On November 8, 2011 Nephros received the initial FDA ...
... N.C., Nov. 10, 2011 Max Healthcare, India,s first ... today announced organizational changes that include Dr. Ajay Bakshi ... 1, 2011. The Company also named Dr. Abha Aggarwal ... that Mr. Ranvir Bhandari would be taking the additional ...
Cached Medicine Technology:Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 2Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 3Nephros Receives Initial FDA Response to 510(k) Application for Hemodiafiltration System 4Max Healthcare Announces Organizational Changes 2
(Date:11/27/2014)... In order to enable people to adapt ... an easy way to avoid touching a toilet seat and/or ... a prototype of the patent-pending Toilet Tamer, a device that ... and/or lid in a more sanitary manner. It avoids direct ... Overall, it promotes good hygiene and peace of mind. The ...
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... 27, 2014 Dr. Ronald Receveur, who has ... a few oral health tips before patients dig into the ... and New Albany affordable cosmetic dentistry, and his ... starch and sugar. While the staff wishes everyone a happy ... for how patients can enjoy a feast that is also ...
(Date:11/27/2014)... The Little Gym, we know that being active provides ... a recent study confirmed that regular physical activity can ... Pediatrics found that “Promoting physical activity that involves ... may be important not only for health, but also ... of children; those that were engaging in regular physical ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified ... Christmas discount on PPC service. The discount will be available ... begin on 1 December 2014 and remain valid until midnight ... PPC professional working at Ethane Web Technologies says, "This is ... this big discount would make the service quite affordable for ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2
... speaks to you, do you see what they are saying? ... hear, but recent studies suggest that we use a variety ... speech as something we hear, see and even feel. In ... , a journal of the Association for Psychological Science, psychologist ...
... quality care at Cancer Treatment Centers of America ... of America (CTCA) has opened the nation,s first ... facility is the fourth hospital in the steadily ... Medical Center (Western) extends the comprehensive electronic health ...
... 11 /PRNewswire-USNewswire/ -- The U.S. House of ... Assisted Living Federation of America to help law ... Alert Act (H.R. 632), authored by Congressman Lloyd ... vote."We commend Congressman Doggett for his leadership. This ...
... enable more time for direct resident care, ... increase staff satisfactionPITTSBURGH, Feb. 11 Vocollect ... Partners Management Group (Preferred Care) headquartered in ... in two of its managed skilled nursing ...
... efficacy a building block for health reformWASHINGTON, Feb. ... America,s Health Insurance Plans (AHIP), today issued the ... in the Senate-passed stimulus bill:"At a time when ... serious concern for many Americans, it is critical ...
... Brain sees these as special events, even though result ... News) -- A near-win in gambling stimulates a large ... boosts a person,s motivation to gamble, according to British ... explain why gambling attracts so many people and why ...
Cached Medicine News:Health News:Read my lips: Using multiple senses in speech perception 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 2Health News:Electronic Health Record Advances Patient-Centered Cancer Care at Cancer Treatment Centers of America 3Health News:House Passes ALFA-Supported National Silver Alert Bill 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 2Health News:Preferred Care Partners Management Group Deploys Voice-Assisted Care 3Health News:'Near-Wins' Boost Desire to Keep Gambling 2
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
Medicine Products: